Develop effective broad-spectrum vaccines that contain multiple high potential immunogenic protein fragments of the target pathogen
Understand which immunopeptides are presented by different patient groups.
Run analyses fast, with guaranteed results at speed.
Vaccine development aims to prevent the spread of infectious diseases by providing immunity to individuals against specific pathogens. Despite their emerging importance and the introduction of innovative technologies, the development of vaccines remains a complex and challenging process.
Overall, the identification of effective antigen fragments that ensure broad-spectrum protection against the target pathogen along with the high costs and the high risk of failure, tend to complicate the process.
Immunopeptidomics involves the identification and characterization of peptides (antigens) presented by major histocompatibility complex (MHC) molecules.
ImmuneSpec’s advanced immunopeptidomics platform allows thorough analysis of all pathogenic immunogenic protein fragments in a faster and more accurate way.
By analyzing the ensemble of immune peptides presented by infected cells or in samples from infected patients, researchers can identify the best epitopes for the development of broad-spectrum vaccines against the target pathogen. By incorporating both MHC I and MHC II associated peptides, the resulting vaccine will trigger robust CD4 and CD8 responses.
This approach optimizes vaccine development and selects high-quality leads through the identification of true in vivo antigens. Ultimately, it leads to a more efficient research and development stage, smoother clinical trials, and faster market approval.
Institute of Tropical Medicine Antwerp
Experience the benefits of our high-quality products and exceptional service.